Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. A team at Heriot-Watt University, Edinburgh, leading the clinical ...

Prostate zonal anatomy is best demonstrated with MRI. On T2-weighted sequences, the normal prostate can be divided into the peripheral zone, which shows high signal intensity owing to its high water ...

In metastatic prostate cancer, AI-facilitated quantification of metastatic burden, accurate identification of castration resistance, and prediction of treatment sensitivity and resistance are active ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...